Company news

Cumberland Pharmaceuticals Inc. news in 2026

Cumberland Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cumberland Pharmaceuticals announces plans to file New Drug Application for ifetroban DMD program

October 26, 2026

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

October 23, 2026

Cumberland Pharmaceuticals provides updated webcast registration link for ifetroban dmd program call

October 23, 2026

Cumberland Pharmaceuticals announces national call to present an update on its ifetroban dmd program

October 19, 2026

Cumberland Pharmaceuticals reports company update & Q2 2026 financial results

August 4, 2026

Cumberland Pharmaceuticals to announce company update & Q2 2026 financial results

July 28, 2026

Cumberland Pharmaceuticals announces special dividend of $1.50 per share

July 13, 2026

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

July 1, 2026

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

June 26, 2026

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

June 2, 2026

Cumberland Pharmaceuticals announces launch of Vibativ® in China

May 28, 2026

Cumberland Pharmaceuticals reports Q1 2026 financial results & company update

May 5, 2026

Cumberland Pharmaceuticals to announce Q1 2026 financial results & company update

April 28, 2026

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

April 23, 2026

Cumberland Pharmaceuticals announces expanded indication for Caldolor® (ibuprofen) injection and launch of new brand website

April 15, 2026

Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

March 18, 2026

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

March 17, 2026

Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)

March 9, 2026

Cumberland Pharmaceuticals reports 31% fourth quarter 2025 revenue growth

March 2, 2026

Cumberland Pharmaceuticals launches U.S. promotion of Talicia®

February 24, 2026

Cumberland Pharmaceuticals to announce 2025 annual financial results & company update

February 24, 2026

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

February 4, 2026

Calls in 2026

Decks in 2026